The Alliance for Advancing Health Online Invests $7M+ through the Vaccine Confidence Fund to Boost Vaccination Confidence through Social Media
October 14, 2021 12:33 ET | Global Impact
ALEXANDRIA, VA, Oct. 14, 2021 (GLOBE NEWSWIRE) -- The Vaccine Confidence Fund (VCF) is pleased to announce the selection of 33 organizations that will receive grants totaling over $7 million from...
BES_Mark.jpg
ACCELERON PHARMA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of XLRN and Encourages Investors to Contact the Firm
October 01, 2021 11:54 ET | Bragar Eagel & Squire
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
FStar.jpg
F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
August 04, 2021 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
logo.png
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease
July 14, 2021 07:00 ET | Arch Biopartners
TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury
April 15, 2021 07:00 ET | Arch Biopartners
Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammationNovel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists...
PRA_StandardLogo_RGB_Pink.png
PRA’s remote patient monitoring platform selected by Merck KGaA, Darmstadt, Germany to work in combination with its human growth hormone treatment system
April 07, 2021 16:01 ET | PRA Health Sciences, Inc.
RALEIGH, N.C. , April 07, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today that Merck KGaA, Darmstadt, Germany, known in the United States as EMD Serono, selected PRA’s...
TrevenaLogo.jpg
Trevena, Inc. Appoints Marvin H. Johnson, Jr. to Board of Directors
March 18, 2021 07:00 ET | Trevena Inc.
CHESTERBROOK, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
logo.png
Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide
March 16, 2021 08:33 ET | Arch Biopartners
TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for...
BES_Mark.jpg
PANDION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PAND and Encourages Investors to Contact the Firm
February 25, 2021 11:49 ET | Bragar Eagel & Squire
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
logo.png
Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide
February 02, 2021 07:56 ET | Arch Biopartners
TORONTO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the İstanbul...